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doi:10.1016/j.jtcvs.2007.11.037Objective: Various devices have been proposed for ring stabilization in patients with
mitral valve disease. This study reports the intermediate-term results of mitral valve
repair with a new semirigid partial annuloplasty ring in a large series of patients.
Methods: A total of 437 consecutive patients were analyzed who underwent mitral
valve reconstruction with annuloplasty using the Colvin–Galloway Future band at
the German Heart Center in Munich between 2001 and 2005. A total of 237 patients
(54.2%) underwent isolated mitral valve repair, and 200 patients (45.8%) underwent
a combined procedure. The follow-up is 97% complete (mean follow-up of 405 sur-
vivors 2.1 6 1.1 years).
Results: Overall 30-day mortality was 2.7%. Twenty patients (4.6%) died later after
an average of 1.16 1.1 years. Actuarial survival at 4 years after isolated mitral valve
reconstruction and combined procedures was 91% 6 4% and 87% 6 2.5%, respec-
tively (P , .001). Twelve patients (2.7%) required a mitral valve reoperation after
an average of 4.56 4.3 months. Five of these reoperations were required for band de-
hiscence, and 1 reoperation was required for band fracture. Freedom from reoperation
at 4 years was 97% 6 0.9%. At the latest follow-up, 93.5% of the patients showed
trivial or mild mitral valve regurgitation, and 86.4% of the patients showed New
York Heart Association functional class I or II.
Conclusion: Mitral valve annuloplasty with the Colvin–Galloway Future band can be
performed with a low early and late mortality and an excellent functional outcome.
The low incidence of reoperation demonstrates that the Colvin–Galloway Future
band is a safe and effective device. The importance of secure anchoring of the device
in the mitral annulus has to be emphasized to prevent band dehiscence.
M
itral valve (MV) reconstruction is the treatment of choice for the majority of
patients with MV disease. Because of the pioneering work of Alain Car-
pentier, reconstructive MV surgery is now standardized with documented
excellent long-term results.1-4 MV prosthetic ring annuloplasty is well established and
has contributed significantly to the excellent long-term outcome.5 In 1969, Carpent-
ier1 stated that ‘‘the ring restores the normal geometry of the mitral annulus, decreases
tension on suture lines, increases the leaflet coaptation, and prevents annular dila-
tion.’’1 Although the ring prosthesis as an adjunct to MV repair is generally accepted,
there has been an ongoing discussion about the ideal device. Today, complete rigid,
flexible, semirigid, and partial devices are in use.4,6-8 None of these annuloplasty
devices fulfill all the requirements for an optimal MV function, such as preservation
of the physiologic dynamics of the MV annulus, restoration of an anterior–posterior
ratio of 3:4, and preservation of the 3-dimensional annular saddle-shape.7 The Col-
vin–Galloway (CG) Future annuloplasty band is a new semirigid partial annuloplasty
ring first introduced in October of 2001 by Medtronic (Medtronic Inc, Minneapolis,
Minn). The present study reports for the first time on the intermediate-term resultsThe Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1087
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AF 5 atrial fibrillation
CABG 5 coronary artery bypass grafting
CG 5 Colvin–Galloway
LV 5 left ventricular
MV 5 mitral valve
NYHA 5 New York Heart Association
SAM 5 systolic anterior movement
of MV repair with this new device in a large series of patients
with a complete follow-up, focusing on the quality of the re-
pair, incidence of reoperation, symptomatic improvement,
and functional outcome.
Materials and Methods
A total of 437 patients aged 18 years or more underwent repair for
mitral insufficiency with the CG Future annuloplasty band from
December of 2001 to December of 2005 at the German Heart Center
Munich. During the same time period, a Carpentier Physio ring
(Carpentier-Edwards Physio annuloplasty ring; Edwards Lifescien-
ces LLC, Irvine, Calif) was implanted in 42 patients at special sur-
geons’ preference and MV replacement was performed in 142
patients. These patients were not included in the study. Patients
living outside of Europe were excluded from the study because of
the inherent difficulty of accurate follow-up. A total of 271 patients
(62%) were men, and the average age at operation was 63.76 13.3
years (range 18–87 years). Preoperative clinical and hemodynamic
data are summarized in Table 1. Clinical symptoms, hemodynamic
data, and functional outcome were obtained from medical records,
patients’ follow-up visits, mailed questionnaires, telephone inter-
views with the patient or family members, and communications
from the referring physicians. A total of 373 of 405 patients
(92%) had an echocardiographic assessment at a mean of 1.8 6
1.1 years after the operation. Echocardiographic examinations
were performed by a single investigator with a Siemens Sequoia
Acuson System using a 2.5-MHz imaging transducer and included
M-mode, continuous-wave 2-dimensional, pulsed-wave Doppler,
and color Doppler analyses. The severity of regurgitation was clas-1088 The Journal of Thoracic and Cardiovascular Surgery c Masified as none/trivial (0), mild (I), moderate (II), and severe (III) and
was assessed in a semiquantitative manner by means of color Dopp-
ler flow mapping. For detection of regurgitation, a color flow Dopp-
ler was used with a Nyquist limit (aliasing velocity of 50–60 cm/sec)
and a color gain that just eliminated random color speckle from non-
moving areas. The vena contracta was measured in the parasternal
long-axis view as the narrowest portion of the jet that occurred at
the orifice. The color flow sector was as narrow as possible with
the least depth to maximize lateral and temporal resolution.
All evaluations were carried out according to standard tech-
niques recommended by the American Society of Echocardiogra-
phy. In 356 patients (81.5%), the preoperative New York Heart
Association (NYHA) functional class was assessed retrospectively:
Thirteen patients (3.7%) demonstrated NYHA class I, 66 patients
(18.5%) demonstrated NYHA class II, 222 patients (62.4%) demon-
strated NYHA class III, and 55 patients (15.4%) demonstrated
NYHA class IV. Twenty-six patients (6%) had a history of preoper-
ative myocardial infarction at an average of 5.16 6.6 years (median
1.9 years) before the operation. A total of 283 patients (64.8%) pre-
sented with sinus rhythm, 132 patients (30.2%) presented with atrial
fibrillation (AF), 1 patient presented with complete atrioventricular
block, and 21 patients (4.8%) had undergone a previous pacemaker
implantation. Twenty-one patients (4.8%) had previously under-
gone another cardiac operation.
Etiologic diagnosis was based on medical history and intraoper-
ative and histologic findings. The cause was myxomatous degener-
ation in 287 patients (65.7%), ischemic in 85 patients (19.5%),
infectious in 31 patients (7.1%), congenital in 9 patients (2.1%),
and rheumatic in 6 patients (1.4%). Eight patients (1.8%) presented
with Barlow disease, and 11 patients (2.5%) showed other abnor-
malities. Patients classified as having Barlow disease were usually
younger and presented with a larger MV annulus with excess tissue
of both mitral leaflets.
Operative Data
Thirteen patients underwent operation on an emergent basis. An
emergent operation was defined as being required within 24 hours
after diagnosis. Fifteen patients required an urgent operation, usu-
ally with 48 to 72 hours after diagnosis. A total of 237 patients
(54.2%) underwent isolated MV repair; 131 of these patients
(55.3%) underwent operation through a minimal invasive right
anterolateral incision. A total of 200 patients (45.8%) underwentTABLE 1. Preoperative patient characteristics
Variable All patients Isolated MV repair Combined procedures P value
No. of patients 437 237 200
Age (y) Mean 6 SD 63.7 6 13.3 60.8 6 13.2 67.3 6 12.5 ,.001
Male sex n (%) 271 (62) 156 (66) 115 (57.5) .074
Non-sinus rhythm n (%) 154 (35.2) 74 (31.2) 80 (40) .056
Preoperative pacemaker n (%) 21 (4.8) 4 (1.7) 17 (8.5) .002
NYHA functional class $ III n (%) 268 (61) 129 (54) 139 (69.5) ,.001
LVEF (angiography) (%) Mean 6 SD 57.9 6 15.3 62.4 6 11.7 52.6 6 17.2 ,.001
Previous myocardial infarction n (%) 26 (6) 4 (2) 22 (11) ,.001
Previous cardiac operation n (%) 21 (5) 5 (2) 16 (8) .004
Previous MV surgery n (%) 6 (1) 3 (1) 3 (1.5) .834
MV, Mitral valve; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; SD, standard deviation.y 2008
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cedures included coronary artery bypass grafting (CABG) (n5 79),
tricuspid valve surgery (n 5 48), or aortic valve surgery (n 5 36).
Twenty-five patients underwent MV repair in combination with
CABG and tricuspid or aortic valve surgery. Other associated pro-
cedures in 12 patients included left ventricular (LV) aneurysm resec-
tion, aortic aneurysm resection, left atrial myxoma resection, and
atrial septal defect closure. Twenty-nine patients with preoperative
persistent AF underwent a modified maze procedure.
Operative Technique
All operations were performed on cardiopulmonary bypass under
systemic hypothermia (26C–32C). Myocardial protection was
achieved using cold (4C) crystalloid antegrade cardioplegia
(Bretschneider solution) or warm-blood cardioplegia. The MV
was exposed through a left atrial or right atrial transseptal approach.
Segmental valve analysis was performed as described by Carpentier
and colleagues.4 Sizing was primarily based on the length of the
anterior leaflet. Thus, band size was chosen so that the sizer was
not totally covered by the anterior leaflet to leave sufficient space
for the posterior leaflet to allow for optimal coaptation. In addition,
the intertrigonal distance serves as an additive dimension to find an
optimal correlation between the height and the width of the anterior
leaflet. The majority of patients (82.2%) received a Future band size
28 to 32. The size of the Future band and the number of patients were
as follows (size 26 [n 5 4], size 28 [n 5 126], size 30 [n 5 112],
size 32 [n 5 121], size 34 [n 5 67], and size 36 [n 5 7]. Different
repair techniques were applied during the study period (Table 2). All
patients were discharged with a regimen of phenprocoumon (Cou-
madin) for the first 3 months postoperatively. After 3 months, anti-
coagulant therapy was continued only in patients with chronic and
paroxysmal AF.
Follow-up
Complete follow-up was achieved in 97%, yielding a cumulative
total of 858 patient-years. The follow-up was closed on December
31, 2006. As of January of 2007, 405 patients are alive (mean
follow-up 2.16 1.1 years, median 1.3 years). Postoperative compli-
cations were analyzed according to the ‘‘Guidelines for Reporting
Morbidity and Mortality after Cardiac Valvular Operations’’ ap-
proved by the Society of Thoracic Surgeons.




Isolated ring annuloplasty 93 21.3
PML segmental resection 88 20.1
PML segmental resection 1 sliding/folding plasty 63 14.4
Chordal replacement with PTFE sutures 65 14.9
Edge-to-edge Alfieri technique 42 9.6
Dreyfus technique 10 2.3
Whooler-type suture 5 1.1
Chordal shortening 2 0.5
Combined procedures 69 15.8
Total 437 100
PML, Posterior mitral leaflet; PTFE, polytetrafluoroethylene.The Journal of ThorStatistical Analysis
Statistical analysis was performed with the Statistical Package for
Social Science release 14 (SPSS Inc, Chicago, Ill). Continuous
variables are reported as mean 6 1 standard deviation in the tables
and text, and categoric variables are reported as percentages. The
chi-square test (for categoric variables) and Mann–Whitney test
(for continuous variables) were used to determine statistical differ-
ences. The Kaplan–Meier method was used to estimate the late
and event-free survival probabilities. Survival estimates are reported
as the mean6 1 standard error. The log-rank test was used to ascer-
tain differences between groups.
Results
The mean cardiopulmonary bypass time was 107 6 27 min-
utes for isolated MV repair and 138 6 49 minutes for
combined procedures (P , .001). The mean aortic cross-
clamping time for isolated MV repair and combined pro-
cedures was 78 6 22 minutes and 96 6 27 minutes,
respectively (P, .001). Fourteen patients (3.2%) with a com-
bined procedure required intraaortic balloon pump assistance
postoperatively. The mean length of hospital stay after solated
and combined MV repair was 9 6 3 days and 12 6 7 days,
respectively (P , .001)
Mortality
The overall 30-day mortality was 2.7% (n 5 12/437). None
of the 237 patients who underwent isolated MV repair died
within 30 days postoperatively. The 30-day mortality was
7.6% (6/79) for MV reconstruction and CABG, 6.3% (3/
48) for concomitant tricuspid valve surgery, 2.8% (1/36)
for concomitant aortic valve replacement, and 15.4% (2/13)
for MV reconstruction with concomitant CABG and tricus-
pid/aortic valve surgery. Overall 30-day mortality was
1.96% (8/409) in electively performed operations, 6.7% (1/
15) in urgent operations, and 23.1% (3/13) in emergent oper-
ations. Twenty patients (4.6%) died late after an average of
1.1 6 1.1 years. The cause of death was assessed retrospec-
tively in 20 of 32 patients (63%). Seven patients (35%) died
of a cardiac-related cause, and 13 patients died of a noncar-
diac-related cause. The actuarial survival probability at 4
years was 89.9% 6 2.2% for all patients, 91% 6 4% for
patients who underwent isolated MV repair, and 87% 6
2.5% for patients who underwent a combined procedure
(P , .001) (Figure E1). The 4-year actuarial survival of
patients with degenerative and ischemic MV disease was
96% 6 2% and 81.3% 6 6%, respectively (P , .001).
Reoperation
Twelve patients (2.7%) required an MV-related reoperation
4.5 6 4.3 months after the initial operation (Table 3); 3 of
those were performed at another institution: The indication
for reoperation was recurrent mitral regurgitation caused by
CG Future band dehiscence (n 5 5), chordal rupture (n 5
1), leaflet suture dehiscence (n5 2), progression of ischemicacic and Cardiovascular Surgery c Volume 135, Number 5 1089
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endocarditis (n 5 1), and persistent systolic anterior move-
ment (SAM) (n 5 1). In 10 of these cases, the valve was
replaced with a biologic (n 5 4) or mechanical (n 5 6)
prosthesis, and in 2 of these cases, a repeat MV reconstruc-
tion was performed. Other reoperations included aortic valve
replacement (n 5 1), tricuspid valve replacement (n 5 1),
and CABG (n5 1). Overall freedom from MV-related reop-
eration at 4 years was 97% 6 1.2% for isolated MV repair
and 97% 6 1.3% for combined procedures (P . .05)
(Figure E2). The reoperation rate was not different for
patients who underwent isolated MV repair through a median
sternotomy or minimally invasive approach. SAM was diag-
nosed by intraoperative transesophageal echocardiography in
10 patients. Two patients underwent immediate operative
revision (triangular resection of prolapsing A2). Eight pa-
tients were treated medically, and 1 of these patients required
a reoperation because of persistent SAM 1 week after the
initial operation.
Thromboembolism
Thromboembolic complications, such as stroke (n5 4), tran-
sient ischemic attack (n 5 1), pulmonary embolism (n 5 1),
central retinal artery occlusion (n 5 1), and central venous
thrombosis (n 5 1), occurred in 8 patients 1.3 6 1.1 years
(median 0.7 years) after the initial operation. The overall free-
dom from thromboembolism at 4 years after MV repair was
96% 6 1.6%.
Follow-up Status
At the latest follow-up, 405 patients were alive. Preopera-
tively, 67.8% of the patients showed NYHA functional class
III (60.2%) and IV (7.6%). At follow-up, the majority of the




1 CG Future band dehiscence (P1, P2, P3) 6
2 CG Future band dehiscence (P2) 6
3 CG Future band dehiscence (A3, P3) 1
4 CG Future band dehiscence (P2) 4,6
5 CG Future band dehiscence (A1, P1) 1
Leaflet suture dehiscence
2,6
6 Leaflet suture dehiscence 0,7
7 Leaflet suture dehiscence 44
8 Ischemic cardiomyopathy with progressive
LV dilation and recurrent MVR
10
9 Chordal rupture and prolapse (A2, A3) 12
10 MV endocarditis 2.6
11 CG Future band fracture 3.7
12 SAM 7 (d)
CG, Colvin–Galloway; LV, left ventricular; MVR, mitral valve regurgitation;
MV, mitral valve; SAM, systolic anterior movement.1090 The Journal of Thoracic and Cardiovascular Surgery c Mpatients showed a significant functional improvement. 86.4%
of the patients showed NYHA functional class I and II. A to-
tal of 296 of 405 patients (73.1%) presented with sinus
rhythm, 97 patients presented (24%) with AF/flutter, 4 pa-
tients presented with other rhythm disturbances, and 8 pa-
tients were pacemaker dependent. A total of 124 of 132
patients who had presented with AF at hospital admission
are alive. At follow-up, 40 of these patients (32.2%) pre-
sented with sinus rhythm, 80 patients (64.5%) were still in
AF, 3 patients showed other heart rhythm disturbances, and
1 patient had required a pacemaker implantation. Seven
patients experienced a major nonfatal bleeding complication
1.4 6 1.2 years (median 1.1 year) after the initial operation.
Four of the 7 patients were taking phenprocoumon. Freedom
from bleeding complications after 4 years was 93%6 4.4%.
At the latest follow-up, 124 of 405 survivors (30.6%) were
taking phenprocoumon. Echocardiographic examination,
including the preoperative results of the 12 patients who re-
quired a reoperation, revealed no or mild mitral regurgitation
in 338 of 374 patients (90.4%), moderate mitral regurgitation
in 19 patients (5.1%), and severe mitral regurgitation in 17 pa-
tients (4.5%) (Figures 1 and E3). The mean echocardio-
graphic EF was 55.5% 6 9.5% (median 60%). The results
of echocardiographic examinations at different time intervals
are summarized in Table E1.
Discussion
The present study reports for the first time the midterm results
of a large series of patients who underwent MV reconstruction
with the CG Future band, first introduced by Medtronic in
Europe in October of 2001. The CG Future band is a kidney-
shaped, partial, low-profile, annuloplasty band containing an
elastic stiffener wire made of MP-35N (SPS Technologies,
Jenkintown, Pa), a nonmagnetic, nickel cobalt-chromium-
Figure 1. Mitral valve regurgitation (preoperatively and at latest
follow-up, including the echocardiography results of 12 patients
before reoperation. MR, Mitral regurgitation.ay 2008
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by a polyester fabric (Medtronic Inc, Minneapolis, Minn).
The ratio of the transverse to anterior–posterior internal diam-
eter is approximately 1.75. The wire core forms eyelets at the
trigones to enhance fixation and reduce the anterior ring diam-
eter. Today only a few studies are available reporting results
after MV reconstruction with this device.8,9 There is common
agreement that failure to add an annuloplasty to an MV
reconstructive procedure increases the risk of late reopera-
tion.10-12 During the past 30 years, various devices for MV an-
nuloplasty have been introduced,4,6,13 with major differences
in regard to mechanical flexibility, shape, and completeness
of the ring. The mitral orifice is a dynamic structure with
a complex dynamic interaction between the annulus and
the LV outflow tract.14 The intertrigonal distance normally
expands during diastole, facilitating ventricular filling, and
contracts during systole, thereby improving leaflet coapta-
tion.15,16 Thus, an ideal annuloplasty device should provide
long-term stability of the reconstructive procedure by reduc-
ing stress and strain on the leaflets and the chordal structures,
and provide a low transvalvular gradient and still preserve all
components of a physiologic MV function (eg, restore the an-
terior–posterior ratio, reduce the posterior ring diameter,
maintain the 3-dimensional saddle shape, and allow for a dy-
namic change in annular diameters during the cardiac cycle).
Initially, a complete rigid ring was introduced by Alain
Carpentier; however, this initial device was questioned be-
cause it alleviates the sphincter-like physiologic dynamics
of the mitral annulus and its 3-dimensional saddle shape, mak-
ing its use potentially responsible for the occurrence of LV
outflow tract obstruction17 and SAM,18 as well as the impair-
ment of postoperative LV function.19 It was shown that totally
flexible complete rings, such as introduced by Duran and
Ubago6 in 1976, better preserve LV function than complete
rigid devices and allow for dynamic annular motion.17,20
Therefore, Carpentier later introduced the Physio ring con-
cept,4 a semirigid complete device that is supposed to provide
flexibility to the posterior MV ring, thus allowing annular dy-
namic motion. However, semirigid complete devices restore
the physiologic annular morphology only in 2-dimensions,
while the height of the annulus is flattened, the leaflet curva-
ture is diminished, and the saddle shape is abolished.21
Rationale for Using Partial Annuloplasty Ring
The rationale for using a partial ring device is 2-fold. Gorman
and colleagues22 described a significant movement of the
anterior or fibrotic segment of the MV annulus, although
this has been debated by others.23 A partial ring like the
CG Future band may allow this physiologic intertrigonal an-
nular motion because of its flexibility in the posterior part. By
using 3-dimensional transesophageal echocardiography,
Sharony and associates8 found a 9.6% reduction in orifice
area and a 5.2% reduction in intertrigonal distance during
systole with the CG Future band, which was not observedThe Journal of Thorawith the Carpentier-Edwards rigid ring. Consequently, they
also noted a significant difference in the mean transvalvular
gradients, being 4.0 6 0.3 mm Hg with the CG Future
band and 5.0 6 0.3 mm Hg with the Carpentier-Edwards
rigid ring.8 In the present investigation, the mean transvalvu-
lar gradient was 2.96 1.4 mm Hg and thus somewhat lower
than the 3.556 1.93 mm Hg reported by Carpentier and col-
leagues4 in another study using the Physio ring. A second ra-
tionale for using partial devices may be seen in the dynamic
interaction between the MV annulus and the LV outflow
tract, in that the anterior annulus tilts away from the LV out-
flow tract and toward the left atrium during systole.17,24,25
The preservation of this physiologic deformation could po-
tentially be important in avoiding LV outflow tract obstruc-
tion after ring annuloplasty. In an experimental study on
sheep, it was shown that these physiologic annular folding
dynamics were only preserved with a partial flexible ring
(Tailor ring, St Jude Medical, Inc, St. Paul, Minn), but not
with a complete flexible ring (Duran ring, Medtronic
Inc).26 Furthermore, it was shown recently that mitral annu-
lus deformation is closely related to aortic root dynamics in
that aortic root reduction during diastole participates in mitral
annulus dilatation.16 Allowing more cyclic changes in annu-
lar motion partial ring devices, such as the CG Future band,
may also interfere less with the LV outflow tract. A potential
disadvantage of partial rings might be seen in an insufficient
reduction of the anterior portion of the mitral annulus. In
postmortem studies of hearts from patients with ischemic
and dilated cardiomyopathy, Hueb and colleagues27 showed
that the dilatation of the mitral annulus affects not only the
muscular but also the fibrous portion. In an ovine model of
ischemic mitral regurgitation, Gorman and colleagues22
also demonstrated progressive dilatation of both the anterior
and posterior part of the mitral annulus. This potential draw-
back of partial rings was addressed in the design of the CG
Future band by the construction of the eyelets, which are sup-
posed to be anchored in the fibrous trigones, thus also reduc-
ing the anterior part of the annulus. The CG Future band is
supposed to allow remodeling of the anterior–posterior diam-
eter and dynamic expansion of the intertrigonal distance dur-
ing the cardiac cycle and may interfere less with the motion
between the mitral annulus and the LV outflow tract than
completely rigid rings.
Quality of Repair
In addition to the hemodynamic performance of annuloplasty
devices, the stability of the valve reconstruction at long term,
expressed by the recurrence of mitral regurgitation, deserves
the main focus when choosing a device. In this respect, the
incidence of repair failure is similar to that of semirigid and
flexible rings.11 Few studies have reported functional results
after CG Future band implantation. In a study of 40 patients
with a mean follow-up of 16.5 6 5.7 months, Fasol and col-
leagues9 found no or 11 mitral regurgitation in 91.1% ofcic and Cardiovascular Surgery c Volume 135, Number 5 1091
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patients with the CG Future band were found to have either
no or trace mitral insufficiency with no difference to patients
with the Carpentier-Edwards Classic ring. In the present se-
ries, 90.4% of patients showed no or mild mitral regurgitation
at the latest follow-up after 2.1 6 1.1 years. This compares
favorably to functional results after implantation of the Car-
pentier–Edwards Physio ring. Carpentier and colleagues4 re-
ported that 94.7% of the patients exhibited no, and 5.3% mild
residual mitral regurgitation 12 months after repair. Accola
and colleagues28 found no-trace-trivial or 11 insufficiency
in 89.4% of patients and 21 in 10.6% of patients 3.2 6 1.7
years after the initial operation. Failure of valve reconstruc-
tion is rare. In the study by Accola and colleagues,28 11 of
492 patients (2.3%) required a reoperation because of recon-
struction failures 4.3 to 87.7 months after MV repair with the
Physio ring. In one case, the ring was dislodged. The freedom
from reoperation at 4 years was 81.5%6 2.1%. According to
Carpentier and colleagues,4 only 4 of 137 patients (2.9%)
who underwent annuloplasty with a Physio ring had to un-
dergo reoperation. In our study, 12 patients (2.7%) required
a reoperation 4.5 6 4.3 months after the initial operation.
Procedure-related failures, such as CG Future band dislodg-
ment and suture dehiscence, were the main reasons. Dis-
lodgement of the device occurred in 5 of 11 patients, 4 at
the posterior ring/commissure and 1 at the anterior commis-
sure. Apparently the forces exerted on the posterior part of the
ring are higher than with a complete device, where the radiant
traction forces are dissipated over the entire annulus. All of
these events occurred in the beginning of our experience
with the CG Future band, with only 1 incidence occurring
after the year 2003. Thus, we emphasize the importance of
exact placement of the annuloplasty sutures deep and pre-
cisely into the mitral annulus to ensure secure fixation. One
patient presented with CG Future band fracture. The fracture
occurred at the midpoint of the CG Future band and led to re-
current annular dilatation. One incidence of a fracture was re-
ported by Hartrumpf and colleagues:29 The metal skeleton
broke near the posteromedial commissure. To date, in excess
of 20,000 CG Future bands have been implanted, and the
reported overall incidence of fractures is approximately
0.09% (communication by the manufacturer: Medtronic
Inc, February 6, 2007). Consequently, the specification for
the CG Future band wire stiffener material was updated by
Medtronic Inc with respect to dimensional tolerances, alloy
chemistry, and mechanical properties. In the present study,
freedom from MV-related reoperation at 4 years after MV re-
construction was 97% 6 1.2% with no difference between
patients who underwent isolated MV repair or a combined
procedure. All reoperations have been performed early
within the first year after MV repair. In a series of 1072 pa-
tients who underwent isolated MV repair with 4 different an-
nuloplasty techniques, Gillinov and colleagues12 report a 10-
year freedom from reoperation rate of 93%. By using the1092 The Journal of Thoracic and Cardiovascular Surgery c MPhysio ring, Accola and colleagues28 found a freedom from
reoperation at 4 and 7 years of 81.5% 6 2.1% and 67.9%
6 4.6%, respectively. With the use of the Carpentier Classic
ring in 120 patients, Soyer and colleagues30 found freedom
from reoperation at 5 years to be 95.2%. Thus, the functional
results after repair with the CG Future band are excellent
and in line with previous reports using other annuloplasty
devices.
Thromboembolism
Many studies do not describe the anticoagulation regimen or
the incidence of AF. In our series, all patients were dis-
charged with a regimen of phenprocoumon for the first 3
months postoperatively. The referring physicians were ad-
vised to continue anticoagulation therapy in patients with
AF. The freedom from thromboembolism at 4 years after
MV repair was 96%6 1.6% for all patients, which compares
favorably to other studies in which freedom from thrombo-
embolism was found to be 93% 5 years after repair with
a Carpentier Classic ring.30
Mortality
In our series, the overall 30-day mortality was 2.74%, with no
death in the isolated MV repair group and 6% in the combined
procedure group. This compares favorably to the results of
other studies in which complete or open semirigid, flexible,
or rigid annuloplasty rings were used. In a series of 137 pa-
tients with isolated MV reconstruction using the Physio
ring, Carpentier and colleagues4 reported an early mortality
of 2%. Gillinov and co-authors12 analyzed 1072 patients
with isolated MV repair with a Cosgrove–Edwards band or
a Carpentier–Edwards Classic ring and reported a hospital
mortality of 0.3%. Accola and colleagues28 analyzed 492
patients who underwent MV reconstruction with a Physio
ring and reported a hospital mortality of 2.1% for isolated
MV reconstruction and 4.9% for patients with concomitant
CABG. The actuarial survival probability at 4 years in the
present study was 91% 6 4% for isolated MV repair and
87% 6 2.5% for combined procedures. Accola and col-
leagues28 observed an actuarial survival at 4 years of 81.5%
6 2.1%, not differentiating between isolated and combined
procedures.
Study Limitations
Our study is a retrospective study with all of the inherent
limitations. In addition, the influence of the competing risk
of death has to be considered when the event-free survival
from valve-related complications, such as thromboembolism,
bleeding, or reoperation, is calculated according to the Ka-
plan–Meier method, because the probability of reoperation,
for example, may be overestimated when the patients who
died before the event occurred are censored.ay 2008
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Presently, MV reconstruction in patients with isolated MV
disease is performed with a low operative mortality (Gillinov
and colleagues:12 0.3%; Carpentier and colleagues:4 2%; Ac-
cola and colleagues:28 2.1%; German Heart Center: 0%). The
functional results are excellent. A significant symptomatic
improvement can be achieved in more than 95% of patients,
the majority of the patients present with no or mild residual
mitral regurgitation,4,8,9 and the incidence of reoperation is
low (Carpentier and colleagues:4 2.9%; Accola and col-
leagues:28 2.2%; German Heart Center: 2.7%). Ring annulo-
plasty is a key factor in the efficacy of these operations,4,12
whereas the type of annuloplasty does not seem to have
a significant influence, at least in terms of survival and repair
durability.
We demonstrated that MV reconstruction using the CG
Future band can be performed with a low 30-day and late
mortality and an excellent functional outcome. The low
incidence of reoperation demonstrates that the CG Future
band is a safe and effective device for mitral annuloplasty.
The secure fixation of this device, especially in the posterior
part of the annulus, is of the utmost importance.
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Surgery for Acquired Cardiovascular Disease Lange et alFigure E1. Actuarial survival after MV repair. Kaplan–Meier esti-
mate of survival for patients who underwent isolated MV repair or
MV repair with concomitant CABG and/or aortic/tricuspid valve
surgery. Survival estimates are reported as the mean6 1 standard
error. The actuarial survival probability at 4 years was 91% 6 4%
for patients who underwent isolated MV repair and 87% 6 2.5%
for patients who underwent a combined procedure. MV, Mitral
valve.1093.e1 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Lange et al Surgery for Acquired Cardiovascular DiseaseFigure E2. Freedom from MV-related reoperation. Kaplan–Meier
estimate of freedom from reoperation for patients who underwent
isolated MV repair or MV repair with concomitant CABG and/or
aortic/tricuspid valve surgery. Freedom from MV-related reopera-
tion at 4 years was 97%6 1.2% for isolated MV repair and 97%6
1.3% for combined procedures. Estimates of freedom from reoper-
ation are reported as the mean 6 1 standard error. MV, Mitral
valve.A
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Surgery for Acquired Cardiovascular Disease Lange et alFigure E3. Freedom from severe MVR. Kaplan–Meier estimate of
freedom from severe MVR. Freedom from severe MVR 4 years after
MV repair was 79.3% 6 10% (mean 6 1 standard error).1093.e3 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Lange et al Surgery for Acquired Cardiovascular DiseaseTABLE E1. Results of echocardiographic studies at different time intervals (n 5 373 patients)
Date of study #1 y 1 to # 2 y 2 to # 3 y $3 y
Patients (n) 100 121 98 54
Mean 6 SD Mean 6 SD Mean 6 SD Mean 6 SD
Septum (mm) 11.9 6 2.0 11.4 6 2.1 11.8 6 1.5 11.1 6 1.7
Posterior wall (mm) 11.6 6 2.3 11.1 6 2.0 11.7 6 1.5 10.9 6 1.7
LVEDD (mm) 52.3 6 5.5 51.9 6 6.7 51.4 6 5.6 52.5 6 7.9
LVESD (mm) 35.2 6 6.0 34.8 6 6.5 34.5 6 5.3 36.4 6 7.7
LAESD (mm) 44.5 6 6.0 46.8 6 8.8 48.3 6 10.4 48.8 6 9.4
DP (mm Hg) 2.7 6 1.4 2.5 6 1.3 2.5 6 1.0 2.9 6 1.4
EF (%) 55.8 6 10.4 55.2 6 9.1 57.0 6 7.0 52.6 6 11.5
SD, Standard deviation; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LAESD, left atrial end-systolic diameter;
DP, transvalvular pressure gradient; EF, ejection fraction.A
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